IMIDAZO [2,1-B] QUINAZOLIN-2-ONE DERIVATIVES AND THEIR USE AS PLATELET ANTI-AGGREGATIVE AGENTS
    7.
    发明申请
    IMIDAZO [2,1-B] QUINAZOLIN-2-ONE DERIVATIVES AND THEIR USE AS PLATELET ANTI-AGGREGATIVE AGENTS 审中-公开
    咪唑并[2,1-B]喹唑啉-2-酮衍生物及其作为抗肿瘤药物的用途

    公开(公告)号:US20110152298A1

    公开(公告)日:2011-06-23

    申请号:US12993072

    申请日:2009-05-13

    CPC分类号: C07D487/04

    摘要: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below where the substituents have the meanings defined in claim (I) and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.

    摘要翻译: 本发明涉及具有降低心血管副作用潜力的选择性血小板降低剂阿那格雷的取代类似物的发现,其应该导致改善的患者依从性和治疗骨髓增生性疾病的安全性。 更具体地说,本发明涉及具有以下通式的某些咪唑并喹唑啉衍生物,其中取代基具有权利要求(I)中所定义的含义,并且其在人体中可用作血小板降低剂。 本发明的化合物通过抑制巨核细胞吞噬作用并因此起血小板的形成的作用。

    IMIDAZOQUINAZOLINE DERIVATIVES AS ANAGRELIDE ANALOGUES FOR THE TREATMENT OF MYELOPROLIFIC DISEASES AND THROMBOTIC DISEASES
    8.
    发明申请
    IMIDAZOQUINAZOLINE DERIVATIVES AS ANAGRELIDE ANALOGUES FOR THE TREATMENT OF MYELOPROLIFIC DISEASES AND THROMBOTIC DISEASES 审中-公开
    咪达唑仑衍生物作为用于治疗失血性贫血和血栓性疾病的亚硫酸酯类似物

    公开(公告)号:US20110071173A1

    公开(公告)日:2011-03-24

    申请号:US12993054

    申请日:2009-05-13

    CPC分类号: C07D487/04

    摘要: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.

    摘要翻译: 本发明涉及具有降低心血管副作用潜力的选择性血小板降低剂阿那格雷的取代类似物的发现,其应该导致改善的患者依从性和治疗骨髓增生性疾病的安全性。 更具体地,本发明涉及具有以下通式的某些咪唑并喹唑啉衍生物,其中取代基具有权利要求1中定义的含义,并且其在人体中可用作血小板降低剂。 本发明的化合物通过抑制巨核细胞吞噬作用并因此起血小板的形成的作用。